• search

Lupin inks in-licensing pact with Italian pharma major

Written by: Staff

Mumbai, May 15 (UNI) Mumbai-headquartered pharma major Lupin has inked an in-licensing agreement with Italy-based ItalFarmaco under which Lupin will exclusively market the latter's cardiovascular critical care product ''enoxaparin sodium injection'' under the brand name ''Lupenox'' in the Indian market.

A press release issued here today stated that Lupenox will be marketed in pre-filled syringes.

Commenting on the tie-up, Mr Sakti Chakraborty, President-India Region Formulations, Lupin, said, ''In life-critical situations, quality is of paramount importance and we believe that Lupenox, being a superior quality product sourced from ItalFarmaco's USFDA-approved facility, will serve the needs of patients better.'' UNI JJ MAZ SKB1846

For Daily Alerts
Get Instant News Updates
Notification Settings X
Time Settings
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more